Anne Wojcicki, the CEO and a co-founder of 23andMe, tells Nature's Soapbox Science blog that her company is moving toward working with pharmaceutical companies on phase 4, post-marketing studies. The company's database contains data from about 150,000 customers, the blog adds. "We definitely want to connect more and more with pharma partners to leverage the platform we've created," Wojcicki says.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.